Fulgent (FLGT) Reports Q1 2026 Earnings with Revenue Declines and Losses
Fulgent (FLGT) reported Q1 2026 earnings with a revenue decline of 3.2% year-over-year and 14.6% sequentially, driven by reduced sales to a large customer. The company posted a GAAP net loss of $24.8 million, with adjusted EBITDA losses rising to $15.2 million. The results reflect challenges in its precision diagnostics and anatomic pathology segments, though biopharma services showed growth.
Topics: earnings EBITDA financial performance GAAP net loss non-GAAP operating expenses revenue decline